Evidence map›Paper›PMID 32618713›Full record

Trial reportEpidemiology (Cambridge, Mass.)2020

Antenatal Uterotonics as a Risk Factor for Intrapartum Stillbirth and First-day Death in Haryana, India: A Nested Case-control Study.

Sanjana Brahmawar Mohan, Halvor Sommerfelt, J Frederik Frøen, Sunita Taneja, Tivendra Kumar, Kiran Bhatia, Lize van der Merwe, Rajiv Bahl, Jose C Martines, Sarmila Mazumder and 1 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Epidemiology (Cambridge, Mass.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Sanjana Brahmawar MohanFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Halvor SommerfeltCentre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.
J Frederik FrøenCentre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.
Sunita TanejaFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Tivendra KumarFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Kiran BhatiaFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Lize van der MerweCentre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.
Rajiv BahlDepartment of Maternal, Newborn, Child and Adolescent Health, World Health Organization, Geneva, Switzerland.
Jose C MartinesCentre for Intervention Science in Maternal and Child Health (CISMAC) and Centre for International Health (CIH), University of Bergen, Bergen, Norway.
Sarmila MazumderFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Nita BhandariFrom the Centre for Health Research and Development, Society for Applied Studies (SAS), New Delhi, India.
Society for Applied Studies · INNorwegian Institute of Public Health · NOUniversity of Bergen · NOWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundUse of uterotonics like oxytocin to induce or augment labor has been shown to reduce placental perfusion and oxygen supply to the fetus, and studies indicate that it may increase the risk of stillbirth and neonatal asphyxia. Antenatal use of uterotonics, even without the required fetal monitoring and prompt access to cesarean section, is widespread, yet no study has adequately estimated the risk of intrapartum stillbirth and early neonatal deaths ascribed to such use. We conducted a case-control study to estimate this risk.

methodsWe conducted a population-based case-control study nested in a cluster-randomized trial. From 2008 to 2010, we followed pregnant women in rural Haryana, India, monthly until delivery. We visited all live-born infants on day 29 to ascertain whether they were alive. We conducted verbal autopsies for stillbirths and neonatal deaths. Cases (n = 2,076) were the intrapartum stillbirths and day-1 deaths (early deaths), and controls (n = 532) were live-born babies who died between day 8 and 28 (late deaths).

resultsAntenatal administration of uterotonics preceded 74% of early and 62% of late deaths, translating to an adjusted odds ratio (95% confidence interval [CI]) for early deaths of 1.7 (95% CI = 1.4, 2.1), and a population attributable risk of 31% (95% CI = 22%, 38%).

conclusionsAntenatal administration of uterotonics was associated with a substantially increased risk of intrapartum stillbirth and day-1 death. See video abstract: http://links.lww.com/EDE/B707.

Indexed as

Infant MortalityOxytocicsStillbirthCase-Control StudiesFemaleHumansIndiaInfantInfant, NewbornPregnancyPrenatal CareRisk FactorsOxytocics

Identifiers

PMID32618713
PMCPMC7458079
OpenAlexW3038153733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.